InvestorsHub Logo
Followers 234
Posts 26887
Boards Moderated 0
Alias Born 01/12/2013

Re: Laurent Maldague post# 9459

Thursday, 06/27/2013 8:45:42 PM

Thursday, June 27, 2013 8:45:42 PM

Post# of 426713
Not over, This is the the sNDA dated 6-26-2013 posted today at the FDA.
http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/021654Orig1s037ltr.pdf

This is not a small change in my opinion, Lovaza's comercial website has been down since the fall of 2012.
http://www.lovaza.com/

GSK is up to their eye balls in Omega-3 Resolvin Inflamation studies with Brigham and Women's Hospital.
http://clinicaltrials.gov/ct2/show/NCT01301794?term=lovaza&rank=15

Brigham and Women's Hospital holds ALL key Resolvin patents and now I speculate GSK holds two key Omega-3 drugs Lovaza and Vascepa.

GSK and Amarin I believe FIRMLY are "partners".

http://en.wikipedia.org/wiki/Resolvins
http://en.wikipedia.org/wiki/COX-2_inhibitor

GSK and Brigham and Women's Hospital are studing Resolvins FACT.

Resolvins are likey to be cutting edge treament for cancers, CVD, Asthma, DM, Crohn's dz....all inflamation!!! BP could build a $100 Billion per year drug pipline fast on Resolvins.

Resolivins are new science and not discussed at all until last week. I e-mailed Amarin the 25 NIH studies. Maybe they had a seeing Jesus discussion with GSK.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News